Dr. Dalton on Novel Approaches in Uterine Cancer

Video

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses novel approaches emerging in the field of uterine cancer.

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses novel approaches emerging in the field of uterine cancer.

In the uterine cancer field, there have been changes coming over the last few years as researchers are learning more about microsatellite instability (MSI), which is present in select patients with uterine cancers. Additionally, this MSI may be targeted with the use of PD-1 inhibitors, Dalton adds.

Another tumor that is known to be MSI-high includes colorectal cancer, she explains. In the gynecologic field, uterine cancers seem to be the tumor type that have MSI-high characteristics. However, early research suggest that some ovarian cancers may have this, as well.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,